Alkermes plc (ALKS)
-NasdaqGS 29.91 
1.14(3.96%) 4:00PM EDT|After Hours
:
29.91 0.00 (0.00%) 4:31PM EDT
| Prev Close: | 28.77 |
|---|
| Open: | 29.10 |
|---|
| Bid: | 27.23 x 100 |
|---|
| Ask: | 29.90 x 100 |
|---|
| 1y Target Est: | 33.18 |
|---|
| Beta: | 1.12 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 28.77 - 30.20 |
|---|
| 52wk Range: | 15.69 - 34.30 |
|---|
| Volume: | 1,198,194 |
|---|
| Avg Vol (3m): | 1,414,010 |
|---|
| Market Cap: | 4.02B |
|---|
| P/E (ttm): | 166.17 |
|---|
| EPS (ttm): | 0.18 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- The FDA Might Pull This Drug From the Market (and Why It Doesn't Matter)at Motley Fool(Tue 3:20PM EDT)
- Following The Data Leads Alkermes In Right Directionat Investor's Business Daily(Fri, Jun 14)
- Alkermes' CEO Presents at Goldman Sachs Healthcare Conference (Transcript)at Seeking Alpha(Thu, Jun 13)
- Alkermes Changing The Standard Of Care For Schizophreniaat Seeking Alpha(Thu, Jun 13)
- 2 Healthcare Companies With Recent Intensive Insider Sellingat Seeking Alpha(Thu, Jun 13)
- When It Comes To Biotech, Diversity Is Keyat Seeking Alpha(Wed, Jun 12)
- Top-Quality Foreign Stocks Re-Entering Buy Zonesat Investor's Business Daily(Mon, Jun 10)
- A Full Pipeline At Alkermesat Seeking Alpha(Mon, Jun 10)
- Celgene, Biogen Lead IBD 50's Top 5 Biotechsat Investor's Business Daily(Wed, Jun 5)
- Biogen Delays EU Launch of TecfideraZacks(Fri, May 31)
- Alkermes Presents Positive Results from Phase 2 Clinical Study of ALKS 5461 in Major Depressive Disorder at 53rd Annual NCDEU MeetingBusiness Wire(Fri, May 31)
- Encouraging Data from AlkermesZacks(Wed, May 29)
- Amgen-Astellas CollaborateZacks(Wed, May 29)
- Alkermes’ Corporate Presentation to be Webcast at Two Upcoming ConferencesBusiness Wire(Wed, May 29)
- Alkermes' Management Presents at Deutsche Bank 38th Annual dbAccess Health Care Conference (Transcript)at Seeking Alpha(Wed, May 29)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 6.72 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Mar-14)
: | N/A |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.22 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizoph...
View More